Outset Medical bags another $132M to ramp up U.S. expansion for all-in-one dialysis system

Close-up of the touchscreen interface of the Tablo dialysis device
Outset Medical's Tablo Dialysis System is FDA-cleared for use in chronic and acute care settings and is working to expand that label to include home use. (Outset Medical)

Outset Medical raised $132 million in series D capital, which will boost the production capabilities and speed up the commercial expansion of its all-in-one dialysis device.  

The Tablo Hemodialysis System is FDA-cleared for use in chronic and acute care settings. It is designed to simplify and improve dialysis care for patients, caregivers and doctors, expanding “how, when, and where dialysis can be provided,” the company said in a statement.  

The Tablo system eliminates the need for centralized water processing equipment by connecting directly to tap water. It purifies the water and makes dialysis fluid as the patient undergoes treatment. This makes it suitable for use in various settings and could cut costs for hospitals and extended-care facilities, Outset says. 

“Tablo offers patients and healthcare providers a new option for more flexible and convenient dialysis treatment, improving the dialysis experience while at the same time reducing overall dialysis spend,” said Outset CEO Leslie Trigg in the statement 

With sensor-based automation, wireless data transmission and a touchscreen interface, the device may also be used for “self-serve” dialysis, where patients may set up and monitor their own treatment without depending on staff. San Jose, California-based Outset is working on a clinical trial en route to expanding Tablo’s label to include home use. 

More than 661,000 Americans have kidney failure, with about 468,000 of them on dialysis, according to 2015 statistics from the National Institute of Diabetes and Digestive and Kidney Diseases. The National Kidney Foundation has found patients undergoing more frequent, at-home dialysis take less medication to control their blood pressure, experience less restless leg syndrome and have more energy, among other benefits. 

This latest round follows a $60 million series B and a $76.5 million series C, which supported the development of Tablo and scaled up its launch, respectively. Abu Dhabi-based Mubadala Investment Company led the round, joining Outset’s existing backers, Baxter Ventures, Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors, Warburg Pincus and funds advised by T. Rowe Price Associates.